Opendoor stock edges up in premarket after 5% slide as UBS hikes target ahead of earnings
11 February 2026
1 min read

Opendoor stock edges up in premarket after 5% slide as UBS hikes target ahead of earnings

New York, Feb 11, 2026, 08:12 EST — Premarket

  • Opendoor shares paused their slide in premarket trading, finding some footing after tumbling sharply the previous session.
  • UBS left its rating unchanged but bumped up the price target, according to one analyst.
  • Next week’s results, plus the management webcast, have investors lining up.

Opendoor Technologies Inc (OPEN) edged 0.8% higher ahead of the open on Wednesday, trading at $4.73. That uptick comes after a 5.1% drop the day before, when shares settled at $4.69.

Timing makes a difference here. Opendoor is a high-volatility play tied to U.S. housing demand and mortgage rates; traders usually move fast to reprice the stock ahead of earnings.

The company’s approach, known as iBuying, is straightforward: purchase homes outright, then flip them. But this setup doesn’t offer much wiggle room if borrowing costs shift or local prices soften.

UBS’s Stephen Ju bumped his price target on Opendoor up to $5 from $1.60 this day, sticking with a Neutral rating. The analyst described the company’s latest report as “another reset point.” But Ju also pointed out Opendoor has yet to deliver “positive unit economics”—meaning it needs to make money per home once direct costs are covered. StreetInsider.com

Opendoor shares swung from $5.08 to $4.69 on Tuesday, logging volume of roughly 46.9 million, Investing.com data showed. Activity ran strong throughout the session.

Beyond the stock itself, markets showed little movement. Early Wednesday saw S&P 500 futures edging higher by roughly 0.1%, as attention zeroed in on the postponed U.S. January jobs data—numbers that might reshape how traders are betting on rate policy.

Opendoor’s upcoming report puts the spotlight back on how it’s managing cash and inventory. Investors are likely to zero in on EBITDA—since that strips out interest, taxes, depreciation and amortization—looking for any sign of improvement.

They’re eyeing the time homes linger on Opendoor’s balance sheet, along with the funding costs tied to those properties. Even a slight move in home prices can quickly cut into resale margins.

The risk is clear enough: should demand weaken or prices drop, Opendoor could be forced to slash prices on its inventory, locking in losses and ramping up cash burn. Any sign it’s eyeing new capital would immediately revive dilution concerns.

Opendoor plans to post its fourth-quarter and full-year 2025 results after markets close on Feb. 19, with a “Financial Open House” livestream scheduled for 5:00 p.m. ET. Shareholders will be able to submit questions starting Feb. 12 through Robinhood’s Say Technologies platform. barchart.com

Stock Market Today

  • Siren Exits Ascendis Pharma with $50 Million Sale Amid Strong Quarterly Performance
    May 14, 2026, 3:43 PM EDT. On May 14, 2026, investment fund Siren sold its entire stake in Ascendis Pharma A/S, offloading 235,862 shares in a $52.87 million transaction based on first-quarter average prices. The divestment reduced Siren's position by approximately $50.3 million, including sales and market price effects. Despite this exit, Ascendis shares have risen 50% over the past year, outperforming the S&P 500 by 24 percentage points. The Danish biopharma company recently reported robust Q1 results, with revenue doubling to 247 million euros driven by sales of YORVIPATH and SKYTROFA, and recorded a net profit boosted by a deferred tax asset. Ascendis focuses on rare endocrine and pediatric diseases using its TransCon technology. Siren's sale does not signal a negative outlook amid Ascendis' strong momentum and expanding rare disease patient base.

Latest articles

REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

14 May 2026
REGENXBIO shares fell 37% to $6.31 after its Duchenne muscular dystrophy gene therapy, RGX-202, met the main goal in a late-stage trial. Investors reacted to two serious adverse events and uncertainty over FDA approval. The company reported 93% of patients showed microdystrophin expression at 12 weeks. REGENXBIO said it will seek accelerated approval and targets a 2027 launch.
Digi Power X Stock Slides Before Earnings as $1.1 Billion AI Deal Faces First Test

Digi Power X Stock Slides Before Earnings as $1.1 Billion AI Deal Faces First Test

14 May 2026
Digi Power X shares fell 14% to $7.28 in heavy trading Thursday ahead of its first-quarter results and operations update due May 15. Investors are focused on its $1.1 billion, 10-year AI data-center deal with Cerebras and a $19.6 million SubQ AI GPU rental contract launching Friday. The company also expanded its at-the-market share-sale program to $175 million.
Smart Powerr Stock Nearly Quadruples as Nasdaq Delisting Threat Shadows CREG

Smart Powerr Stock Nearly Quadruples as Nasdaq Delisting Threat Shadows CREG

14 May 2026
Smart Powerr shares jumped to 78.83 cents, up nearly 59 cents from the previous close, after hitting 90.37 cents intraday. The surge followed news that Nasdaq warned the company over its sub-$1 share price and possible suspension. Trading volume reached about 395 million shares. The company said a hearing request would delay any suspension but gave no assurance of keeping its Nasdaq listing.
Ondas stock price today: ONDS steadies premarket after 6% slide as Israel demining deal sinks in
Previous Story

Ondas stock price today: ONDS steadies premarket after 6% slide as Israel demining deal sinks in

Accenture stock drops as CEO share-sale filing and $1.4 billion contract protest hit tape
Next Story

Accenture stock drops as CEO share-sale filing and $1.4 billion contract protest hit tape

Go toTop